Document is current
Any future updates will be listed below
-
Authors
Tanaka, Keiko https://orcid.org/0000-0002-3748-5799
Kimura, Eizen
Oryoji, Kensuke
Mizuki, Shin-ichi
Kobayashi, Tomoko
Nishikawa, Atsushi
Yoshinaga, Eiko
Miyake, Yoshihiro
-
Funding
Funding for this research was provided by:
Eli Lilly Japan
- License Information
-
More Information
Article History
Received: 8 February 2021
Accepted: 12 May 2021
First Online: 6 June 2021
Declarations
:
: This study was sponsored by Eli Lilly Japan K.K. Dr. KT has no conflict of interests. Dr. EK has no conflict interests. Dr. KO has received speaking fees from Abbvie, Chugai, Tanabe-Mitsubishi, Astellas, Eisai, Janssen, Pfizer, UCB, Ono, Actelion, Novartis, Sanofi, Asahi-kasei, Ayumi, Teijin, Nihon-Shinyaku, and Eli Lilly. Dr. SM has received speaking fees from Abbvie, Asahi-kasei, Chugai, Eisai, Eli Lilly, Janssen, and Mitsubishi Tanabe. Dr. TK was an employee of Eli Lilly Japan K.K. at the time the study was conducted and is currently an employee of AstraZeneca K.K. Dr. AN is an employee of Eli Lilly Japan K.K. and owns stock in Eli Lilly and Company. Dr. EY is a research consultant for Eli Lilly Japan K.K. Dr. YM has received a research funding from Eli Lilly Japan KK.
: The study protocol was approved by the ethics committee of Ehime University Graduate School of Medicine (No. 1709001).
